Investor Presentaiton slide image

Investor Presentaiton

R&D investor presentation 34 In STEP 1, 34.8% of patients treated with semaglutide reached ≥20% weight loss and reported improved quality of life versus placebo Categorical weight loss Proportion of patients Sema 2.4 mg showed a statistically significant treatment difference versus placebo in the IWQOL-Lite-CT PRO 100% 92.4% 80% 60% 40% 33.1% ■Sema 2.4 mg ■Placebo IQWOL-Lite-CT I 74.8% Physical function 54.8% Physical 34.8% Psychological 20% 11.8% Total 5.0% 2.0% 0% ≥5% ≥10% Weight loss ≥15% ≥20% ETD [95% CI] 9.43 [7.50 11.35] * 9.14 [7.31 10.96] * 10.50 [8.81 12.19] * 10.02 [8.42 11.62] * Favours placebo Favours semaglutide -202468 10 12 14 Descriptive statistic only. Based on the on-treatment data, i.e. data for subjects that are on-treatment at week 68 Sema: semaglutide * statistically significant; p-values other than physical function were not controlled for multiplicity PRO: patient reported outcome; CI: confidence interval, ETD: estimated treatment difference, IWQOL-Lite-CT: Impact of Weight on Quality of Life-lite:
View entire presentation